Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNFα generation from human monocytes by interacting with a 'low-affinity' phosphodiesterase 4 conformer

British Journal of Pharmacology

Volumn 118, Issue 3, 1996, Pages 649-658

  Souness, John E ^a   Griffin, Miriam ^a   Maslen, Christopher ^a   Ebsworth, Karen ^a   Scott, Lisa C ^a   Pollock, Kenneth ^a   Palfreyman, Malcolm N ^a   Karlsson, Jan Anders ^a  

^a Dagenham Research Centre   (United Kingdom)

Author keywords

Cyclic AMP phosphodiesterase; Monocytes; Rolipram; RP 73401; Tumour necrosis factor

Indexed keywords

CYCLIC AMP; CYCLIC AMP PHOSPHODIESTERASE; CYCLIC GMP; ISOENZYME; LIPOPOLYSACCHARIDE; MESSENGER RNA; PHOSPHODIESTERASE INHIBITOR; PICLAMILAST; POLYADENYLATED RNA; PROSTAGLANDIN E2; ROLIPRAM; TRITIUM; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BRAIN MEMBRANE; CONTROLLED STUDY; DRUG MECHANISM; DRUG PROTEIN BINDING; ENANTIOMER; ENZYME INHIBITION; ENZYME INHIBITOR INTERACTION; GENE EXPRESSION; HUMAN; HUMAN CELL; ISOTOPE LABELING; MONOCYTE; NORMAL HUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0029982516     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1476-5381.1996.tb15450.x     Document Type: Article

References (45)

1. ALVAREZ, R., SETTE, C., YANG, D., EGLEN, R.M., WILHELM, R., SHELTON, E.R. & CONTI, M. (1995). Activation and selective inhibition of a cyclic AMP-specific phosphodiesterase, PDE-4D3. Mol. Pharmacol., 48, 616-622.
2. ASHTON, M., COOK, D.C., FENTON, G., KARLSSON, J.-A., PALFREYMAN, M.N., RAEBURN, D., RATCLIFFE, A.J., SOUNESS, J.E., THURAIRATNAM, S. & VICKER, N. (1994). Selective type IV phosphodiesterase inhibitors as anti-asthmatic agents. The synthesis and biological activities of 3-cyclopentyloxy-4-meth oxybenzamides and analogues. J. Med. Chem., 37, 1696-1703.
3. BARNETTE, M.S., GROUS, M., CIESLINSKI, L.B. BURMAN, M., CHRISTENSEN, S.B. & TROPHY, T.J. (1995a). Inhibitors of phosphodiesterase IV (PDE IV) increase acid secretion in rabbit isolated gastric glands: Correlation between function and interaction with a high-affinity rolipram binding site. J. Pharmacol. Exp. Ther., 273, 1396-1402.
4. BARNETTE, M.S., MANNING, C.D., CIESLINSKI, L.B., BURMAN, M., CHRISTENSEN, S.B. & TORPHY, T.J. (1995b). The ability of phosphodiesterase IV inhibitors to suppress superoxide production in guinea-pig eosinophils is correlated with inhibition of phosphodiesterase4 catalytic activity. J. Pharmacol. Exp. Ther., 273, 674-679.
5. BEAVO, J. A. & REIFSNYDER, D.H. (1990). Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors. Trends Pharmacol. Sci., 11, 150-155.
6. BOLGER, G. (1994). Molecular biology of the cyclic AMP-specific cyclic nucleotide phosphodiesterases: A diverse family of regulatory enzymes. Cell. Signalling, 6, 851-859.
7. BOLGER, G., MICHAELI, T., MARTINS, T., ST JOHN, T., STEINER, B., RODGERS, L., RIGGS, M., WIGLER, M. & FERGUSON, K. (1993). A family of human phosphodiesterases homologous to the dunce learning and memory gene product of Drosophila melanogaster are potential targets for anti-depressant drugs. Mol. Cell. Biol., 13, 6558-6571.
8. ENGELS, P., FITCHEL, K. & LUBBERT, H. (1994). Expression and regulation of human and rat phosphodiesterase type IV isogenes. FEBS Lett., 350, 291-295.
9. FAUCI, A.S., SCHNITTMAN, S.M., POLI, G, KOENIG, S. & PANTALEO, G. (1991). Immunopathogenic mechanisms in human immunodeficiency virus (HIV) infection. Ann. Intern. Med., 114, 678-693.
10. FAZELY, F., DEZUBE, B.J., ALLEN-RYAN, J., PARDEE, A.B. & RUPRECHT, R.M. (1991). Pentoxifylline (Trental) decreases the replication of the human immunodeficiency virus type I in human peripheral blood mononuclear cells and cultured T-cells. Blood, 11, 1653-1656.
11. FEUERSTEIN, G.Z., LIU, T. & BARONE, F.C. (1994). Cytokines, inflammation and brain injury: Role of the tumour necrosis factor-α. Cerebrovasc. Brain. Metab. Rev., 6, 341-360.
12. GENAIN, C.P., ROBERTS, T., DAVIS, R.L., NGUYEN, M.-H., UCCELLI, A., FAULDS, D., LI, Y., HEDGPETH, J. & HAUSER, S.L. (1995). Prevention of autoimmune demyelination in non-human primates by a cAMP-specific phosphodiesterase inhibitor. Proc. Natl. Acad. Sci. U.S.A., 92, 3601-3605.
13. HARRIS, A.L., CONNELL, M.J., FERGUSON, E.W., WALLACE, A.M., GORDON, R.J., PAGANI, E.D. & SILVER, P.J. (1989). Role of low Km cyclic AMP phosphodiesterase inhibition in tracheal relaxation and bronchodilation in the guinea-pig. J. Pharmacol. Exp. Ther., 251, 199-206.
14. HINSHAW, L.B., EMERSON, T.E., TAYLOR, F.B., CHANG, A.C.K., DUERR, M., PEER, G.T., FLOURNOY, D.J., WHITE, G.L., KOSANSKE, S.D., MURRAY, C.K., XU, R., PASEY, R.B. & FOURNEL, M.A. (1992). Lethal Staphylococcus aureus-induced shock in primates: Prevention of death with anti-TNF antibody. J. Trauma, 33, 568-573.
15. ISHIKAWA, Y., MUKAIDA, N., KUNO, K., RICE, N., OKAMOTO, S.-I. & MATSUSHIMA, K. (1995) Establishment of lipopolysaccharide-dependent nuclear factor κB activation in cell-free system. J. Biol. Chem., 270, 4158-4164.
16. KAMBAYASHI, T., JACOB, C.O., ZHOU, D., MAZUREK, N., FONG, M. & STRASSMANN, G. (1995). Cyclic nucleotide phosphodiesterase type IV participates in the regulation of IL-10 and the subsequent inhibition of TNF-α and IL-6 release by endotoxin-stimulated macrophages. J. Immunol., 155, 4909-4916.
17. MCLAUGHLIN, M.M., CIESLINSKI, L.B., BURMAN, M., TORPHY, T.J. & LIVI, G.P. (1993). A low-Km, rolipram-sensitive, cAMP-specific phosphodiesterase from human brain. Cloning and expression of cDNA, biochemical characterisation of recombinant protein, and tissue distribution of mRNA. J. Biol. Chem., 268, 6470-6476.
18. MURRAY, K.J., ENGLAND, P.J., HALLAM, T.J., MAGUIRE, J., MOORES, K., REEVES, M.L., SIMPSON, A.W.M. & RINK, T.J. (1990). The effects of siguazodan, a selective phosphodiesterase inhibitor, on human platelet function. Br. J. Pharmacol., 99, 612-616.
19. NEWELL, C.L., DEISSEROTH, A.B. & LOPEZ-BERESTEIN, G. (1994). Interaction of nuclear proteins with an AP-1/CRE-like promoter sequence in the human TNFα gene. J. Leukoc. Biol., 56, 27-35.
20. PALFREYMAN, M.N. & SOUNESS, J.E. (1996) Phosphodiesterase type IV inhibitors. Prog. Med. Chem., 33, 1-52.
21. PRABHAKAR, U., LIPSHUTZ, D., O'LEARY BARTUS, J., SLIVJAK, M.J., SMITH III, E.F., LEE, J.C. & ESSER, K.M. (1994). Characterization of cAMP-dependent inhibition of LPS-induced TNFα production by rolipram, a specific phosphodiesterase IV (PDE IV) inhibitor. Int. J. Immunopharmacol., 16, 805-816.
22. SATRIANO, J. & SCHLONDORFF, D. (1994). Activation and attenuation of transcription factor NF-κB in mouse glomerular mesangial cells in reponse to tumor necrosis factor-α, immunoglobulin G, and adenosine 3′:5′-cyclic monophosphate: Evidence for involvement of oxygen species. J. Clin. Invest., 94, 1629-1636.
23. SCHADE, F.U. & SCHUDT, C. (1993) The specific type III and IV phosphodiesterase inhibitor zardavarine suppesses formation of tumor necrosis factor by macrophages. Eur. J. Pharmacol., 230, 9-14.
24. SCHMEICHEN, R., SCHNEIDE, H.H. & WACHTEL, H. (1990). Close correlation between behavioral responses and binding in vivo for inhibitors of the rolipram-sensitive phosphodiesterase. Psychopharmacology, 102, 17-20.
25. SCHNEIDER, H.H., SCHMIECHEN, R., BREZINSKI, M. & SEIDLER, J. (1986). Stereospecific binding of the antidepressant rolipram to brain protein structures. Eur. J. Pharmacol., 127, 105-115.
26. SEKUT, L., YARNALL, D., STIMPSON, S.A., NOEL, L.S., BATEMANFITE, R., CLARK, R.L., BRACKEEN, M.F., MENIUS, L.A. & CONNOLLY, K.M. (1995). Anti-inflammatory activity of phosphodiesterase (PDE) IV inhibitors in acute and chronic models of inflammation. Clin. Exp. Immunol., 100, 126-132.
27. SEMMLER, J., WACHTEL, H. & ENDRES, S. (1993). The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-α production by human mononuclear cells. Int. J. Immunopharmacol., 15, 409-413.
28. SETTE, C., VICINI, E. & CONTI, M. (1994). The rat PDE3 IVd phosphodiesterase gene codes for multiple proteins differentially activiated by cAMP-dependent protein kinase. J. Biol. Chem., 269, 18271-18274.
29. SOMMER, N., LOSCHMANN, P.-A., NORTHOFF, G.H., WELLER, M., STEINBRECHER, A., STEINBACH, J.P., LICHTENFELS, R., MEYERMANN, R., RIETHMULLER, A., FONTANA, A., DICHGANS, J. & MARTIN, R. (1995). The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis. Nature Med., 1, 244-248.
30. SOUNESS, J.E., CARTER, C.M., DIOCEE, B.K., HASSALL, G.A., WOOD, L.J. & TURNER, N.C. (1991). Characterization of guinea-pig eosinophil phosphodiesterase activity. Assessment of its involvement in regulating superoxide generation. Biochem. Pharmacol., 42, 937-945.
31. SOUNESS, J.E., MASLEN, C. & SCOTT, L.C. (1992). Effects of solubilization and vanadate/glutathione complex on inhibitor potencies against eosinophil cyclic AMP-specific phosphodiesterase. FEBS Lett., 302, 181-184.
32. SOUNESS, J.E., MASLEN, C., WEBBER, S., FOSTER, M., RAEBURN, D., PALFREYMANN, M.N., ASHTON, M.J. & KARLSSON, J.-A. (1995). Suppression of eosinophil function by RP 73401, a potent and selective inhibitor of cyclic AMP-specific phosphodiesterase: comparison with rolipram. Br. J. Pharmacol., 114, 39-46.
33. SOUNESS, J.E. & SCOTT, L.C. (1993). Stereospecificity of rolipram actions on eosinophil cyclic AMP-specific phosphodiesterase. Biochem. J., 291, 389-395.
34. SOUNESS, J.E., THOMPSON, W.J. & STRADA, S.J. (1985). Adipocyte cyclic nucleotide phosphodiesterase activation by vanadate. J. Cyclic Nucleotide Protein Phosphorylation Res., 10, 383-396.
35. THOMPSON, W.J. ROSS, C.P., PLEDGER, W.J., STRADA, S.J., BANNEWR, R.L. & HERSH, E.M. (1976). Cyclic adenosine 3′:5′-monophosphate phosphodiesterase. Distinct forms in human lymphocytes and monocytes. J. Biol. Chem., 251, 4922-4929.
36. THOMPSON, W.J., TAN, B.H. & STRADA, S.J. (1991). Activation of rabbit liver high-affinity cAMP (Type IV) phosphodiesterase by vanadyl-glutathionc complex. J. Biol. Chem., 266, 17011-17019.
37. THOMPSON, W.J., TERASAKI, W., EPSTEIN, P.M. & STRADA, S.J. (1979). Assay of cyclic nucleotide phosphodiesterase and resolution of multiple molecular forms of the enzyme. Adv. Cyclic Nucloetide Res., 10, 69-92.
38. TORPHY, T.J. (1994). Inhibitors of phosphodiesterase isozymes: new therapeutic possibilities for asthma. In Bronchitis V. ed. Postma. D. & Gerritson, J. pp. 303-316. Assen: Van Gorcum & Co.
39. TORPHY, T.J., STADEL, J.M., BURMAN, M., CIESLINSKI, L.B., MCLAUGHLIN, M.M., WHITE, J.R. & LIVI, G.P. (1992). Coexpression of human cAMP-specific phosphodiesterase activity and high-affinity rolipram binding in yeast. J. Biol. Chem., 267, 1798-1804.
40. TRACEY, K.J. & CERAMI, A. (1993). Tumour necrosis factor, other cytokines and disease. Annu. Rev. Cell Biol., 9, 317-343.
41. VERGHESE, M.W., MCCONNELL, R.T., LENHARD, J.M., HAMACHER, L. & JIN, S.-L.C. (1995). Regulation of distinct cyclic AMP-specific phosphodiesterase (phosphodiesterase type 4) isozymes in human monocytic cells. Mol. Pharmacol., 47, 1164-1171.
42. WAAGE, A. SORENSEN, M. & STORDAL, B. (1990). Differential effect of oxpentifylline on tumour necrosis factor and interleukin-6 production. Lancet, 335, 543.
43. WANG, P., WU, P., SIEGEL, M.I., EGAN, R.W. & BILLAH, M.M. (1995). Interleukin (IL)-10 inhibits factor κB (NFκB) activation in human monocytes. IL-10 and IL-4 suppress cytokine synthesis by different mechanisms. J. Biol. Chem., 270, 9558-9563.
44. WHITE, J.R., TORPHY, T.J., CHRISTENSEN, S.B., LEE, J.A. & MONG, S. (1990). Purification and characterization of the rolipram sensitive, low Km phosphodiesterase from human monocytes FASEB J., 4, A1987.
45. WILLIAMS, R.O., FELDMAN, M. & MAINI, R.N. (1992). Anti-tumour necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc. Natl. Acad. Sci. U.S.A., 89, 9784-9788.